{"id":400726,"date":"2020-12-16T07:03:43","date_gmt":"2020-12-16T12:03:43","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=400726"},"modified":"2020-12-16T07:03:43","modified_gmt":"2020-12-16T12:03:43","slug":"casi-pharmaceuticals-announces-appointment-of-chief-financial-officer","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/casi-pharmaceuticals-announces-appointment-of-chief-financial-officer\/","title":{"rendered":"CASI Pharmaceuticals Announces Appointment Of Chief Financial Officer"},"content":{"rendered":"<div class=\"xn-newslines\">\n<p class=\"xn-distributor\">PR Newswire<\/p>\n<\/p><\/div>\n<div class=\"xn-content\">\n<p>\n        <span class=\"xn-location\">ROCKVILLE, Md.<\/span>, and <span class=\"xn-location\">BEIJING<\/span>, <span class=\"xn-chron\">Dec. 16, 2020<\/span> \/PRNewswire\/ &#8212; CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a U.S. biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products, today announces the appointment of Weihao Xu to the position of Chief Financial Officer. Mr. Xu will report to Dr. <span class=\"xn-person\">Wei-Wu He<\/span>, Chairman and CEO of CASI.<\/p>\n<div class=\"PRN_ImbeddedAssetReference\" id=\"DivAssetPlaceHolder1\">\n<p>\n          <a href=\"https:\/\/mma.prnewswire.com\/media\/124566\/casi_pharmaceuticals_logo.html\" target=\"_blank\" rel=\"nofollow noopener noreferrer\"><br \/>\n            <img decoding=\"async\" src=\"https:\/\/mma.prnewswire.com\/media\/124566\/casi_pharmaceuticals_logo.jpg\" title=\"CASI Pharmaceuticals logo (PRNewsFoto\/CASI Pharmaceuticals, Inc.)\" alt=\"CASI Pharmaceuticals logo (PRNewsFoto\/CASI Pharmaceuticals, Inc.)\" \/><br \/>\n          <\/a>\n        <\/p>\n<\/p><\/div>\n<p>Most recently, in <span class=\"xn-chron\">January 2020<\/span>, Mr. Xu founded and served as Chief Investment Officer for Permanence Capital LLC, a healthcare-dedicated investment firm. From <span class=\"xn-chron\">February 2018<\/span> until <span class=\"xn-chron\">March 2019<\/span>, he served as Chief Financial <span id=\"spanHghlt6fc2\">Officer for<\/span> 111, Inc. a <span class=\"xn-location\">Shanghai<\/span>-based digital healthcare company, where he led the initial public offering of the company on NASDAQ, and oversaw the company&#8217;s financial operations, corporate strategy and investor relations. Prior to that, Mr. Xu served as a portfolio manager and investment analyst at Matthews International Capital Management LLC, a <span class=\"xn-location\">San Francisco<\/span>-based investment firm focusing on investing in <span class=\"xn-location\">Asia<\/span>, from 2016 to 2018 and subsequently from 2019 to 2020. He also served as head of emerging markets and portfolio manager in <span class=\"xn-location\">New York<\/span> at Permal Asset Management LLC from 2014 to 2016 and investment analyst in <span class=\"xn-location\">London<\/span> at Lansdowne Partners from 2012 to 2014. Mr. Xu holds a Master of Philosophy degree in Accounting from Columbia\u00a0Business School.<\/p>\n<p>&#8220;We are very pleased to welcome Weihao to our leadership team. His unique experience encompasses both that of a healthcare-focused buy-side professional and of a CFO \u00a0overseeing financial operations, including areas of financial planning and fundraising. These skills will enable him to significantly contribute to driving a number of our planned strategic initiatives forward in 2021 and beyond,&#8221; said Dr. He.<\/p>\n<p>\n        <b>About CASI Pharmaceuticals<\/b>\n      <\/p>\n<p>CASI Pharmaceuticals, Inc. (&#8220;CASI&#8221; or the &#8220;Company&#8221;) is a U.S. biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products in <span class=\"xn-location\">China<\/span>, <span class=\"xn-location\">the United States<\/span>, and throughout the world. The Company is focused on acquiring, developing and commercializing products that augment its hematology oncology therapeutic focus as well as other areas of unmet medical need. The Company intends to execute its plan to become a leader by launching medicines in the greater <span class=\"xn-location\">China<\/span> market leveraging the Company&#8217;s <span class=\"xn-location\">China<\/span>-based regulatory and commercial competencies and its global drug development expertise. The Company&#8217;s operations in <span class=\"xn-location\">China<\/span> are conducted through its wholly-owned subsidiary, CASI Pharmaceuticals (<span class=\"xn-location\">China<\/span>) Co., Ltd., which is located in <span class=\"xn-location\">Beijing, China<\/span>. The Company has built a commercial team of over 70 hematology and oncology sales and marketing specialists based in <span class=\"xn-location\">China<\/span>. More information on CASI is available at <a target=\"_blank\" href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=3014821-1&amp;h=144090039&amp;u=http%3A%2F%2Fwww.casipharmaceuticals.com%2F&amp;a=www.casipharmaceuticals.com\" rel=\"nofollow noopener noreferrer\">www.casipharmaceuticals.com<\/a>.<\/p>\n<p>\n        <b>Forward-Looking Statements<\/b>\n      <\/p>\n<p>This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act with respect to the outlook for expectations for future financial or business performance, revenue growth, strategies, expectations and goals. Forward-looking statements are subject to numerous assumptions, risks and uncertainties, which change over time. Forward-looking statements speak only as of the date they are made, and we assume no duty to update forward-looking statements. New factors emerge from time to time, and it is not possible for us to predict which factors will arise. In addition, we cannot assess the impact of each factor on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements. Actual results could differ materially from those currently anticipated due to a number of factors.<\/p>\n<div>\n<table cellspacing=\"0\" cellpadding=\"0\" border=\"0\" class=\"prntblns\">\n<tr>\n<td class=\"prnsbts prnrbrs prnvat prnsbbs prnpl6 prnsbls prnpr6\">\n<p class=\"prnews_p\">\n                <span class=\"prnews_span\"><br \/>\n                  <u>COMPANY CONTACT<\/u>:<\/span>\n              <\/p>\n<p class=\"prnews_p\">\n                <span class=\"prnews_span\"><br \/>\n                  <i>CASI Pharmaceuticals, Inc.<\/i><br \/>\n                <\/span>\n              <\/p>\n<p class=\"prnews_p\">\n                <span class=\"prnews_span\">240.864.2643<\/span>\n              <\/p>\n<p class=\"prnews_p\">\n                <span class=\"prnews_span\"><br \/>\n                  <a target=\"_blank\" href=\"mailto:ir@casipharmaceuticals.com\" class=\"prnews_a\" rel=\"nofollow noopener noreferrer\"><br \/>\n                    <u>ir@casipharmaceuticals.com<\/u><br \/>\n                  <\/a><br \/>\n                <\/span>\n              <\/p>\n<\/td>\n<td class=\"prnsbts prnrbrs prnvab prnsbbs prnpl6 prnsbl1 prnpr6\">\n<p class=\"prnews_p\">\n                <span class=\"prnews_span\"><br \/>\n                  <u>INVESTOR CONTACT<\/u>:<\/span>\n              <\/p>\n<p class=\"prnews_p\">\n                <span class=\"prnews_span\"><br \/>\n                  <i>Solebury Trout<\/i><br \/>\n                <\/span>\n              <\/p>\n<p class=\"prnews_p\">\n                <span class=\"prnews_span\">Jennifer Porcelli<\/span>\n              <\/p>\n<p class=\"prnews_p\">\n                <span class=\"prnews_span\">646.378.2962<\/span>\n              <\/p>\n<p class=\"prnews_p\">\n                <span class=\"prnews_span\"><br \/>\n                  <a target=\"_blank\" href=\"mailto:jporcelli@troutgroup.com\" class=\"prnews_a\" rel=\"nofollow noopener noreferrer\">jporcelli@troutgroup.com<\/a><br \/>\n                <\/span>\n              <\/p>\n<\/td>\n<\/tr>\n<\/table><\/div>\n<p>\u00a0<\/p>\n<p>\u00a0<\/p>\n<div class=\"PRN_ImbeddedAssetReference\" id=\"DivAssetPlaceHolder2\"><\/div>\n<p id=\"PURL\">\n        <img loading=\"lazy\" decoding=\"async\" title=\"Cision\" width=\"12\" height=\"12\" alt=\"Cision\" src=\"https:\/\/c212.net\/c\/img\/favicon.png?sn=PH25873&amp;sd=2020-12-16\" \/> View original content to download multimedia:<a id=\"PRNURL\" rel=\"nofollow\" href=\"http:\/\/www.prnewswire.com\/news-releases\/casi-pharmaceuticals-announces-appointment-of-chief-financial-officer-301193871.html\">http:\/\/www.prnewswire.com\/news-releases\/casi-pharmaceuticals-announces-appointment-of-chief-financial-officer-301193871.html<\/a><\/p>\n<p>SOURCE  CASI Pharmaceuticals, Inc.<\/p>\n<\/p><\/div>\n<p>    <img decoding=\"async\" alt=\"\" src=\"https:\/\/rt.prnewswire.com\/rt.gif?NewsItemId=PH25873&amp;Transmission_Id=202012160700PR_NEWS_USPR_____PH25873&amp;DateId=20201216\" style=\"border:0px;width:1px;height:1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>PR Newswire ROCKVILLE, Md., and BEIJING, Dec. 16, 2020 \/PRNewswire\/ &#8212; CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a U.S. biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products, today announces the appointment of Weihao Xu to the position of Chief Financial Officer. Mr. Xu will report to Dr. Wei-Wu He, Chairman and CEO of CASI. Most recently, in January 2020, Mr. Xu founded and served as Chief Investment Officer for Permanence Capital LLC, a healthcare-dedicated investment firm. From February 2018 until March 2019, he served as Chief Financial Officer for 111, Inc. a Shanghai-based digital healthcare company, where he led the initial public offering of the company on NASDAQ, and oversaw the company&#8217;s financial operations, corporate strategy and &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/casi-pharmaceuticals-announces-appointment-of-chief-financial-officer\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;CASI Pharmaceuticals Announces Appointment Of Chief Financial Officer&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-400726","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>CASI Pharmaceuticals Announces Appointment Of Chief Financial Officer - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/casi-pharmaceuticals-announces-appointment-of-chief-financial-officer\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"CASI Pharmaceuticals Announces Appointment Of Chief Financial Officer - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"PR Newswire ROCKVILLE, Md., and BEIJING, Dec. 16, 2020 \/PRNewswire\/ &#8212; CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a U.S. biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products, today announces the appointment of Weihao Xu to the position of Chief Financial Officer. Mr. Xu will report to Dr. Wei-Wu He, Chairman and CEO of CASI. Most recently, in January 2020, Mr. Xu founded and served as Chief Investment Officer for Permanence Capital LLC, a healthcare-dedicated investment firm. From February 2018 until March 2019, he served as Chief Financial Officer for 111, Inc. a Shanghai-based digital healthcare company, where he led the initial public offering of the company on NASDAQ, and oversaw the company&#8217;s financial operations, corporate strategy and &hellip; Continue reading &quot;CASI Pharmaceuticals Announces Appointment Of Chief Financial Officer&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/casi-pharmaceuticals-announces-appointment-of-chief-financial-officer\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2020-12-16T12:03:43+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mma.prnewswire.com\/media\/124566\/casi_pharmaceuticals_logo.jpg\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/casi-pharmaceuticals-announces-appointment-of-chief-financial-officer\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/casi-pharmaceuticals-announces-appointment-of-chief-financial-officer\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"CASI Pharmaceuticals Announces Appointment Of Chief Financial Officer\",\"datePublished\":\"2020-12-16T12:03:43+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/casi-pharmaceuticals-announces-appointment-of-chief-financial-officer\\\/\"},\"wordCount\":588,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/casi-pharmaceuticals-announces-appointment-of-chief-financial-officer\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/124566\\\/casi_pharmaceuticals_logo.jpg\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/casi-pharmaceuticals-announces-appointment-of-chief-financial-officer\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/casi-pharmaceuticals-announces-appointment-of-chief-financial-officer\\\/\",\"name\":\"CASI Pharmaceuticals Announces Appointment Of Chief Financial Officer - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/casi-pharmaceuticals-announces-appointment-of-chief-financial-officer\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/casi-pharmaceuticals-announces-appointment-of-chief-financial-officer\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/124566\\\/casi_pharmaceuticals_logo.jpg\",\"datePublished\":\"2020-12-16T12:03:43+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/casi-pharmaceuticals-announces-appointment-of-chief-financial-officer\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/casi-pharmaceuticals-announces-appointment-of-chief-financial-officer\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/casi-pharmaceuticals-announces-appointment-of-chief-financial-officer\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/124566\\\/casi_pharmaceuticals_logo.jpg\",\"contentUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/124566\\\/casi_pharmaceuticals_logo.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/casi-pharmaceuticals-announces-appointment-of-chief-financial-officer\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"CASI Pharmaceuticals Announces Appointment Of Chief Financial Officer\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"CASI Pharmaceuticals Announces Appointment Of Chief Financial Officer - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/casi-pharmaceuticals-announces-appointment-of-chief-financial-officer\/","og_locale":"en_US","og_type":"article","og_title":"CASI Pharmaceuticals Announces Appointment Of Chief Financial Officer - Market Newsdesk","og_description":"PR Newswire ROCKVILLE, Md., and BEIJING, Dec. 16, 2020 \/PRNewswire\/ &#8212; CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a U.S. biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products, today announces the appointment of Weihao Xu to the position of Chief Financial Officer. Mr. Xu will report to Dr. Wei-Wu He, Chairman and CEO of CASI. Most recently, in January 2020, Mr. Xu founded and served as Chief Investment Officer for Permanence Capital LLC, a healthcare-dedicated investment firm. From February 2018 until March 2019, he served as Chief Financial Officer for 111, Inc. a Shanghai-based digital healthcare company, where he led the initial public offering of the company on NASDAQ, and oversaw the company&#8217;s financial operations, corporate strategy and &hellip; Continue reading \"CASI Pharmaceuticals Announces Appointment Of Chief Financial Officer\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/casi-pharmaceuticals-announces-appointment-of-chief-financial-officer\/","og_site_name":"Market Newsdesk","article_published_time":"2020-12-16T12:03:43+00:00","og_image":[{"url":"https:\/\/mma.prnewswire.com\/media\/124566\/casi_pharmaceuticals_logo.jpg","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/casi-pharmaceuticals-announces-appointment-of-chief-financial-officer\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/casi-pharmaceuticals-announces-appointment-of-chief-financial-officer\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"CASI Pharmaceuticals Announces Appointment Of Chief Financial Officer","datePublished":"2020-12-16T12:03:43+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/casi-pharmaceuticals-announces-appointment-of-chief-financial-officer\/"},"wordCount":588,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/casi-pharmaceuticals-announces-appointment-of-chief-financial-officer\/#primaryimage"},"thumbnailUrl":"https:\/\/mma.prnewswire.com\/media\/124566\/casi_pharmaceuticals_logo.jpg","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/casi-pharmaceuticals-announces-appointment-of-chief-financial-officer\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/casi-pharmaceuticals-announces-appointment-of-chief-financial-officer\/","name":"CASI Pharmaceuticals Announces Appointment Of Chief Financial Officer - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/casi-pharmaceuticals-announces-appointment-of-chief-financial-officer\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/casi-pharmaceuticals-announces-appointment-of-chief-financial-officer\/#primaryimage"},"thumbnailUrl":"https:\/\/mma.prnewswire.com\/media\/124566\/casi_pharmaceuticals_logo.jpg","datePublished":"2020-12-16T12:03:43+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/casi-pharmaceuticals-announces-appointment-of-chief-financial-officer\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/casi-pharmaceuticals-announces-appointment-of-chief-financial-officer\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/casi-pharmaceuticals-announces-appointment-of-chief-financial-officer\/#primaryimage","url":"https:\/\/mma.prnewswire.com\/media\/124566\/casi_pharmaceuticals_logo.jpg","contentUrl":"https:\/\/mma.prnewswire.com\/media\/124566\/casi_pharmaceuticals_logo.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/casi-pharmaceuticals-announces-appointment-of-chief-financial-officer\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"CASI Pharmaceuticals Announces Appointment Of Chief Financial Officer"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/400726","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=400726"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/400726\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=400726"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=400726"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=400726"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}